Stock DRRX DURECT CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials DURECT Corporation

Equities

DRRX

US2666055007

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-05 pm EDT 		5-day change 1st Jan Change
1.31 USD +2.34% Intraday chart for DURECT Corporation +1.55% +122.03%
May. 21 DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis CI
May. 21 Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 731 420.6 224.3 78.84 17.6 40.66 - -
Enterprise Value (EV) 1 731 420.6 224.3 78.84 17.6 40.66 40.66 40.66
P/E ratio -31.7 x - -6.16 x -2.23 x -0.56 x -1.55 x -1.24 x -1.11 x
Yield - - - - - - - -
Capitalization / Revenue 24.7 x 14 x 16 x 4.09 x 2.06 x 4.02 x 2.25 x 1.72 x
EV / Revenue 24.7 x 14 x 16 x 4.09 x 2.06 x 4.02 x 2.25 x 1.72 x
EV / EBITDA - - - - - - - -
EV / FCF 68,118,185 x -10,808,518 x - - - - - -
FCF Yield 0% -0% - - - - - -
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 19,236 20,318 22,751 22,786 29,829 31,039 - -
Reference price 2 38.00 20.70 9.859 3.460 0.5900 1.310 1.310 1.310
Announcement Date 3/3/20 3/4/21 3/7/22 3/7/23 3/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 29.56 30.11 13.98 19.28 8.548 10.11 18.04 23.65
EBITDA - - - - - - - -
EBIT 1 -19.15 -12.62 -34.27 -35.08 -36.88 -25.88 -32.1 -38.34
Operating Margin -64.78% -41.89% -245.21% -181.93% -431.49% -255.94% -177.94% -162.11%
Earnings before Tax (EBT) 1 -20.58 -14.34 -36.26 -35.33 -27.62 -28.31 -33.09 -37.57
Net income 1 -20.58 -0.582 -36.26 -35.33 -27.62 -28.85 -33.09 -37.57
Net margin -69.6% -1.93% -259.46% -183.23% -323.16% -285.24% -183.43% -158.85%
EPS 2 -1.200 - -1.600 -1.550 -1.050 -0.8467 -1.060 -1.180
Free Cash Flow 10.73 -38.91 - - - - - -
FCF margin 36.3% -129.23% - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 3/3/20 3/4/21 3/7/22 3/7/23 3/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 7.297 1.915 2.076 11.98 3.315 2.054 2.081 1.744 2.669 1.827 2.492 2.558 2.73
EBITDA - - - - - - - - - - - - -
EBIT 1 -6.512 -10.37 -11.09 -2.132 -11.5 -11.02 -10.05 -9.557 -6.254 -5.717 -5.479 -6.329 -8.866
Operating Margin -89.24% -541.31% -534.01% -17.8% -346.85% -536.61% -482.99% -547.99% -234.32% -312.92% -219.89% -247.39% -324.75%
Earnings before Tax (EBT) 1 -7.008 -10.84 -11.55 -2.471 -10.47 -11.99 -11.18 -3.015 -1.441 -7.643 -5.546 -6.446 -9.438
Net income 1 -7.008 -10.84 -11.55 -2.471 -10.47 -11.99 -11.18 -3.015 -1.441 -7.643 -5.801 -6.694 -9.217
Net margin -96.04% -566.16% -556.41% -20.63% -315.81% -583.59% -537.29% -172.88% -53.99% -418.34% -232.8% -261.66% -337.63%
EPS 2 -0.3000 -0.5000 -0.5000 -0.1000 -0.4600 -0.5000 -0.4600 -0.1100 -0.0500 -0.2500 -0.1700 -0.1967 -0.2600
Dividend per Share - - - - - - - - - - - - -
Announcement Date 3/7/22 5/4/22 8/4/22 11/2/22 3/7/23 5/8/23 8/9/23 11/13/23 3/27/24 5/13/24 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 10.7 -38.9 - - - - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 0.16 0.21 - - - - - -
Capex / Sales 0.52% 0.69% - - - - - -
Announcement Date 3/3/20 3/4/21 3/7/22 3/7/23 3/27/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for DURECT Corporation

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.31 USD
Average target price
6.75 USD
Spread / Average Target
+415.27%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
DURECT CORPORATION Stock DURECT Corporation
+122.03% 40.66M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.61% 122B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+17.75% 112B
ARGENX SE Stock argenx SE
+17.23% 25.91B
BIONTECH SE Stock BioNTech SE
-24.11% 19.33B
GENMAB A/S Stock Genmab A/S
-18.56% 16.17B
BEIGENE, LTD. Stock BeiGene, Ltd.
-18.47% 15.6B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-47.75% 14.65B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+57.35% 14.34B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.62% 14B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. DRRX Stock
  4. Financials DURECT Corporation